Search results for: 'future+of+logistics'

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

13 May 2021  |  Global  |  Market Research

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Infographics

×

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Indu...